0
Orphan Designations
2
FDA Approvals
Latest: VYVGART HYTRULO (2023)
8
Active Trials
200 recruiting
3
Rare Diseases
across 7 areas
0
News (30d)
Quiet
argenx US is a company with 0 orphan drug designations across 3 rare diseases, including 2 FDA-approved therapies. Active clinical trials in 8 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| amyotrophic lateral sclerosis | - | Des.TrialAppr. |
| chronic inflammatory demyelinating polyradiculoneuropathy | - | Des.TrialAppr. |
| spinal muscular atrophy | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio